A new study led by researchers at the Hospital for Special Surgery (HSS) suggests that currently available therapies may help ...

While there have been reports from drugmakers about possible interruptions with FDA matters due to staff layoffs, one company ...

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your ...

REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting, taking place in New Orleans, May 13 through 17, 2025. The ...

plans to convene a panel of outside experts before deciding on the company's cell therapy for a heart condition related to Duchenne muscular dystrophy (DMD). Reuters, the news and media division ...

technology to address muscular dystrophies such as Duchenne Muscular Dystrophy Joint presentation with Prevail Therapeutics, a part of Lilly’s Gene Therapy Division, to highlight Scribe’s ...

to treat Duchenne muscular dystrophy (DMD) in patients aged 6 years and older who can walk. Conditional marketing authorization is granted when the benefit of immediate availability outweighs the ...

The purpose of this report is to re-evaluate such a therapeutic program in muscular dystrophy when the drugs are used singly, in combination and with or without exercise. Objective serial ...

Chronic muscle inflammation in Duchenne muscular dystrophy (DMD) is driven by both infiltrating and resident macrophages, the latter stimulated by CSF-1 produced by fibro/adipogenic progenitors.